{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:12Z","timestamp":1790661072068,"version":"4.1.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA018125"],"award-info":[{"award-number":["R01DA018125"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052937"],"award-info":[{"award-number":["R01DA052937"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Opioid withdrawal can be expressed as both a spontaneous and precipitated syndrome. Although spontaneous withdrawal is well-characterized, there is no operational definition of precipitated opioid withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>People (<jats:italic>N<\/jats:italic> = 106) with opioid use disorder maintained on morphine received 0.4 mg intramuscular naloxone and completed self-report (Subjective Opiate Withdrawal Scale, SOWS), visual analog scale (VAS), Bad Effects and Sick, and observer ratings (Clinical Opiate Withdrawal Scale, COWS). Time to peak severity and minimal clinically important difference (MCID) in withdrawal severity were calculated. Principal component analysis (PCA) during peak severity were conducted and analyzed with repeated measures analyses of variance (ANOVA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Within 60 min, 89% of people reported peak SOWS ratings and 90% of people had peak COWS scores as made by raters. Self-reported signs of eyes tearing, yawning, nose running, perspiring, hot flashes, and observed changes in pupil diameter and rhinorrhea\/lacrimation were uniquely associated with precipitated withdrawal. VAS ratings of Bad Effect and Sick served as statistically significant severity categories (0, 1\u201340, 41\u201380, and 81\u2013100) for MCID evaluations and revealed participants' identification with an increase of 10 [SOWS; 15% maximum percent effect (MPE)] and 6 (COWS; 12% MPE) points as meaningful shifts in withdrawal severity indicative of precipitated withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Data suggested that a change of 10 (15% MPE) and 6 (12% MPE) points on the SOWS and COWS, respectively, that occurred within 60 min of antagonist administration was identified by participants as a clinically meaningful increase in symptom severity. These data provide a method to begin examining precipitated opioid withdrawal.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1141980","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T20:30:48Z","timestamp":1682022648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Operational definition of precipitated opioid withdrawal"],"prefix":"10.3389","volume":"14","author":[{"given":"Kelly E.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Elizabeth","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia L.","family":"Bergeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin D.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"B1","volume-title":"Opioid Withdrawal","author":"Shah","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management","volume":"45","author":"Pergolizzi Jr","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108212","DOI":"10.1016\/j.drugalcdep.2020.108212","article-title":"Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome","volume":"215","author":"Dunn","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1124\/jpet.119.258004","article-title":"Non-opioid neurotransmitter systems that contribute to the opioid withdrawal syndrome: a review of preclinical and human evidence","volume":"371","author":"Dunn","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e12680","DOI":"10.1111\/adb.12680","article-title":"Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes","volume":"25","author":"Dunn","year":"2020","journal-title":"Addict Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamapsychiatry.2017.1838","article-title":"Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial","volume":"74","author":"Dunn","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse."},{"key":"B9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoact Drugs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e8149","DOI":"10.5867\/medwave.2021.03.8149","article-title":"Minimal clinically important difference: the basics","volume":"21","author":"Salas Apaza","year":"2021","journal-title":"Medwave."},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone","volume":"30","author":"Antoine","year":"2021","journal-title":"Am J Addict"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in people who use fentanyl","volume":"16","author":"Varshneya","year":"2021","journal-title":"J Addict Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict."},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dar.13017","article-title":"High-dose buprenorphine for treatment of high potency opioid use disorder","volume":"39","author":"Danilewitz","year":"2020","journal-title":"Drug Alcohol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2117128","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1141980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T14:22:40Z","timestamp":1682086960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1141980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":15,"alternative-id":["10.3389\/fpsyt.2023.1141980"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1141980","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"article-number":"1141980"}}